Oklahoma's Medicaid MU payments over by $800K

The Oklahoma Health Care Authority (OHCA) has made incorrect Medicaid Meaningful Use incentive payments to healthcare professionals totaling $888,250, according to a report from the Department of Health and Human Services' Office of Inspector General (OIG).

The OIG found that $888,250 was paid to 47 hospital-based professionals after the agency misinterpreted the time frame for determining hospital-based status. OHCA also claimed $127,500 more than it paid because it mistakenly included six duplicate payments in its report to the Centers for Medicare & Medicaid Services (CMS). The data also did not include a $21,250 payment because of data transmission problems to the repository and lack of reconciliation procedures. 

The OIG recommended that the state refund the federal government the $888,250 in overpayments as well as the $127,500 in over-reported payments, ensure that the $21,250 is successfully transmitted and establish procedures to reconcile the CMS report with the National Level Registry.

The OIG has audited seven other state agencies and found incorrect Medicaid EHR incentive payments in Louisiana and Massachusetts in 2014 and in Arkansas and Texas earlier this year.

Access the report.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.